Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

Epilepsy Clinical Trial

Official title:

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy Until Being Confirmed (EPILIVE Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00522522
• Other study ID #: N01292
• Secondary ID: EPILIVE
• Status: Completed
• Phase: N/A
• First received: August 27, 2007
• Last updated: May 29, 2012
• Start date: February 2008
• Est. completion date: July 2008

Study information

• Verified date: May 2012
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Observational

Clinical Trial Summary

Naturalistic, multicentre, epidemiological study to evaluate the care services used during the process of diagnosis of any kind of epilepsy. Data about services since first seizure until confirmed diagnosis will be examined.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Patients of both sexes 16 years old or older, being diagnosed of any kind of EPILEPSY (criteria ILAE) and with diagnosis being confirmed by a Neurologist over the last 6 months and with write informed consent.

Exclusion Criteria:

• Patients with epilepsy diagnosis confirmed by a Neurologist over the last 6 months before the study or with incapacity to fulfill the requirements of the study.

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Epilepsy

Locations

Country	Name	City	State
United States	UCB Pharma	Smyrna	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
UCB Pharma

Country where clinical trial is conducted

United States,